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ABSRACT 
Objective:  To assess the efficacy of surgery and radiotherapy for the medulloblastoma. 
Material and Methods:  It is a study of fifteen (15) cases of Medulloblastoma operated at The Department of 
Neurosurgery Quaid-e-Azam Medical College / B.V. Hospital Bahawalpur. Study span is three years from 
January 2004 to December 2006 with follow up period of 5 years. 
Results:  Age range was 2 – 12 years with average age of 7 years. Eight (8) patients were male and seven (7) 
were female. In all patients surgery was performed. Radiotherapy (Craniospinal Axis) was given to all but two 
patients who expired before the initiation of radiotherapy, one patient died, two week after surgery and second 
patient, one month after surgery. Out of Thirteen (13) patients who were treated by surgery and radiotherapy, 4 
died before 5 year of age (between 3 and5 year of age) and 9 patients were alive at 5 year follow up. So, our 3 
year survival rate was 86.66% and 5 year survival rate was 60 %.Chemotherapy was not given to any patient. 
Mortality after surgery was 13.33%. 
Conclusion:  It is concluded that mainstay of treatment for medulloblastoma is surgery followed by radiotherapy 
to the whole craniospinal axis. 
Key words:  Medulloblastoma, Radiotherapy, Chemotherapy, Posterior Fossa Syndrome. 
Abbreviations:  PNET: Primitive neuroectodermal tumour, CNS = Central Nervous System. 
 
INTRODUCTION 
Medulloblastoma is a long name made up of three 
smaller words: medulla = Latin for marrow, meaning 
inner substance or core; blastos = Greek word for 
germ, meaning young, primitive, not fully developed; 
and oma = Greek for tumor. In other words, this is a 
tumor of primitive, undeveloped cells located inside 
the cerebellum.
1
 
 Medulloblastoma is the most common malignant 
brain tumour in children accounting for 15 – 20% of 
primary CNS tumors and about 40% of all posterior 
fossa tumors. This is highly invasive embryonal neuro-
epithelial tumor arising in the cerebellum and have the 
tendency to disseminate throughout the CNS early in 
its course.
5
 
 One half of primary brain tumors in children 
originate in the posterior fossa. Medulloblastomas are 
highly malignant brain tumors; they are the most com-
mon malignant posterior fossa tumors in paediatric 
population. They are characterized by their tendency 
to seed along the neuraxis, following CSF pathways, 
and they represent one of the few brain tumors, includ-
ing ependymomas, pineablastoma and lymphoma, to 
metastasize to extra neural tissues. Originally classi-
fied as a glioma, medulloblastoma is now referred to 
as a primitive neuroectodermal tumour (PNET).
12-16
 
 The exact cause(s) of medulloblastoma are not 
known. It does not appear to “run in families” or to be 
directly inherited from the parents. However, medullo-
blastoma is associated with certain chromosomal abn-
ormalities that probably occur at some point during a 
child’s development. This includes not only develop-
Muhammad Arshad, et al 
-123-         Pak. J. of Neurol. Surg. – Vol. 17, No. 2, Jul. – Dec., 2013 
ment after birth, but also the prenatal period before a 
baby is born, while it is still a growing embryo or 
fetus. One possible cause that has been suggested is 
exposure of the fetus to certain causative viruses or 
environmental agents, but this theory remains under 
investigation.
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MATERIALS AND METHODS 
It is study of 15 patients of Medulloblastoma who 
were operated for their disease at The Department of 
Neurosurgery Quaid-e-Azam Medical College / Baha-
wal Victoria Hospital Bahawalpur. Study span is three 
years from January 2004 to December 2006 with fol-
low-up period of 5 years. 
 
RESULTS 
Age range was 2 to 12 years with average age of seven 
(7) years. 
 
Sex Incidence 
Eight (8) patients were male and seven (7) were 
female (Table 1). 
 
Table 1:  Sex Incidence. 
 
Sex No. of Patients Percentage 
Male   8 53.33% 
Female   7 46.67% 
Total 15 100% 
 
Surgical Procedures 
In all the patients V. P. Shunt was inserted, in two pat-
ients at the time of Tumour surgery and in thirteen pat-
ients, about one week before surgery of tumor to reli-
eve the symptoms of hydrocephalus and reduce the 
intracranial pressure which was a facilitating factor for 
the tumor surgery. All the patients but two, who died 
within one month of surgery, underwent radiotherapy 
 
Table 2:  Treatment Offered. 
 
No. of 
Patients 
V.P. 
Shunt 
Surgery Radiotherapy 
No 15 15 13 
Percentage 100% 100% 86.66% 
treatment, about four week after surgery. Craniospinal 
axis radiotherapy was given to all these remaining 
thirteen (13) patients (Table 2). In all the patients the 
main diagnostic tool was MRI scan before and after 
surgery. Post-Op MRI was performed, 72 hours after 
surgery to evaluate any residual tumour and extent of 
brain edema due to surgical trauma. Chemotherapy 
was not given to any patient. 
 Gross total resection was achieved in eight (8) 
53.33% patients and near total resection was achieved 
in seven (7) 46.66% patients (Table 3). 
 
Table 3:  Extent of Tumour Resection. 
 
Tumour Number Percentage 
Total   8 53.33% 
Near Total 7 46.67% 
 
OUTCOME 
Two (2) patients died within one month of surgery. 
One female patient about 12 years of age, she did well 
after surgery for one week. After that she developed 
dysentry and melaena. We consulted pediatrician for 
her treatment. He took the charge of treatment but she 
did not come out from her illness and expired on 15th 
day of surgery from her GIT problem. Second male 
patient of two years, developed posterior fossa 
syndrome after surgery and after one week of surgery 
he developed meningitis and he could not be saved 
even with our best treatment for meningitis and he 
died one month after surgery (Operative Mortality was 
13.33%). 
 
Table 4:  Survival Rate and Operative Mortality. 
 
Outcome No. of Patients Percentage 
Alive 3 Years 13 86.66% 
Alive 5 Years 09 60.00% 
Operative Mortality 02 13.33% 
 
 Other thirteen (13) patients were subjected to radi-
otherapy after surgery and followed up for 5 years. 
Four (4) patients died before the age of 5 years (bet-
ween 3 and 5 years) and only nine (9) patients could 
reach the age of 5 years with surgical as well as radio-
therapeutic treatment of their illness. So our three (3)
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Table 5:  Survival Rate – Comparison of Various Study. 
 
Study 13 Years 5 Years Survival 10 Years Survival Operative Mortality 
Arshad M., 2013 86.66% 60% 30% 13.33% 
Leon Herisiadis, et al, 1997 – 40.4% 30.9% – 
John Mealey JR, et al, 1997 53% 41% 22% 11% 
John, et al, 2006 
Radiotherapy within 48 Days 
– 81% – – 
After 48 Days – 51% – – 
Jenkind, et al, 1990 – 71% – – 
Macontosh, 1997 – 50% – 5% 
Awasty B.S., 1997 76% 60%   
Khalid T.M., 2008 – 89% – – 
 
year survival rate after surgical and radiotherapeutic 
treatment was 86.66% and five (5) year survival was 
60% (Table 4). 
 
DISCUSSION 
Medulloblastoma is the most common malignant brain 
tumor in children, accounting for 10 – 20% primary 
CNS neoplasms and approximately 40% off all poste-
rior fossa tumors. With aggressive surgery, craniospi-
nal radiotherapy and chemotherapy, more than 50% of 
children with medulloblastoma can be expected to be 
free of disease 5 year later. Using current treatments, 
80 – 90% of those without disseminated disease can be 
cured; however treatment for this disease often results 
in endocrinological and intellectual sequelae.
5
 
 The treatment advised for medulloblastoma is sur-
gical exploration with removal of as much of the 
tumor as possible without increasing unduly the opera-
tive risk. This must be followed by irradiation of the 
entire cerebrospinal axis. The survival rate is greater 
for patients in whom a complete surgical excision of 
the tumor was performed, compared with lesser proce-
dures. While grave prognosis associated with medullo-
blastoma is fully justified, it appears that some hope 
can be given to parents of children with this disease, 
since practically 40% of our patients completing treat-
ment have survived 5 years, and 30%, 10 years.
7
 
 In a study done by Leon Herisiadis et al, (59) fifty 
nine children with cerebellar medulloblastoma were 
followed prospectively after they were staged and 
treated consistently with post operative megavoltage 
radiotherapy to the entire neural axis. The probabilities 
of surviving 5 and 10 years were 40.4% 30.9% respec-
tively.
8
 
 John Mealey JR et al reviewed treatments and 
results in 45 cases of medulloblastoma arising in 
children. The surgical mortality rate observed was 
11%. Of those completing postoperative cerebrospinal 
irradiation at this institution, 53% have survived for 3 
years, 41% for 5 years, and 22% for ten years. The 
extent of surgical resection of the cerebellar tumor had 
no significant bearing on prognosis according to their 
study.
9
 
 Certain studies have shown a correlation between 
improved posterior fossa control and shorter periods 
for the completion of radiotherapy.
7
 In Chan et al ser-
ies the 5 year posterior fossa control rate was 81% in 
patients who completed radiotherapy in less than 48 
days, compared with 51% for patients who completed 
radiotherapy in 48 days or more. Recently, adjuvant 
chemotherapy also has been shown to be beneficial in 
children with medulloblastoma.
16,17
 
 A series of 80 cases of medulloblastomas in chil-
dren undergoing operation and postoperatively follo-
wed between 1980 – 1990 at Great Ormond Street 
Hospital for Children has been reviewed and compared 
to an earlier series reported from the same institution 
by Mcintosh. The overall 5 year survival rate for the 
present series was 50%, although 3 patients died after 
surviving 5 years. The operative mortality rate was 
5%. Those patients with no spinal metastasis and total 
tumor removal had a 5 year survival rate of 73%, mak-
ing this the most favorable group in the series.
19
 
 In a study made by Jenkin D et al, for posterior 
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fossa medulloblastoma in childhood for treatment 
results and a proposal for a new staging system, the 
five (5) year survival and disease free survival rates 
were 71% and 64%. It is close to survival rate (60%) 
in our study. Total tumor resection, as determined by 
the surgeon was the most significant favorable prog-
nostic factor.
2
 
 A retrospective review was done by Awasthy BS 
et al in 45 patients at the All India Institute of Medical 
Sciences to assess the outcome and prognostic factors 
for these patients who received post operative radio-
therapy with or without chemotherapy for medullo-
blastoma. The medium age at diagnosis was 11 years. 
Complete macroscopic removal was achieved in 24 
(53.33%) patients and subtotal removal in 21 (46.66%) 
patients and same was the percentage of total and sub-
total removal of tumor in our cases. 41 (91.11%) pati-
ents underwent craniospinal irradiation. In our series 
13 (86.66%) patient were subjected to irradiation treat-
ment after surgery because two patients were died be-
fore the initiation of radiotherapy. Median overall and 
disease free survival was 57 and 31 months and 3 year 
overall survival was 76%.
3
 Our overall 5 year survival 
rate was 60% after combined surgical and radiothe-
rapeutic treatment. Extent of surgery was a significant 
factor for overall survival. 
 51 Paediatric patients with a median age of 7 yea-
rs, the same median age as in our study, were treated 
in the National Cancer Institute – Cairo University. 
Patients were treated by surgery and craniospinal radi-
otherapy. For the pediatric patients the 5 year overall 
survival rate was 89%,
4
 while overall in our study was 
60% (Table 5). 
 
CONCLUSION 
Medulloblastoma is the most common malignant brain 
tumour in children accounting for 15 – 20% of primary 
CNS tumors and about 40% of all posterior fossa 
tumors. This is highly invasive embryonal neuroepi-
thelial tumor arising in the cerebellum and have the 
tendency to disseminate throughout the CNS early in 
its course. 
 The mainstay of treatment for medulloblastoma is 
surgery followed by radiotherapy to the whole cranio-
spinal axis as per literature review. In some high risk 
infant patients' chemotherapy is being given instead of 
radiotherapy after surgery. 
 With aggressive surgery, craniospinal radiotherapy 
and chemotherapy, more than 50% of children with 
medulloblastoma can be expected to be free of disease 
5 year later. Using current treatments, 80 – 90% of 
those without disseminated disease can be cured. 
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